Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 29, 2003

View Archived Issues

Good efficacy and long-term safety described for MT-100 in migraine

Commencement of phase II trial of Cop-1 for Huntington's disease

Guilford awarded grants totaling USD 5.7 million for several programs

Adolor announces positive results in phase III alvimopan study for postoperative ileus

Cardioprotective effects described for pexelizumab after acute myocardial infarction

Gemcabene improves lipid profile of patients with low serum HDL cholesterol levels

Duloxetine effective in improving anxiety associated with depression

No adverse effects reported for safinamide after tyramine challenge

Enhanced activity of novel paclitaxel analogues against drug-resistant breast cancer cells

Metabotropic glutamate receptor agonist as a nonsedative anxiolytic

Evaluation of a novel antiestrogen drug delivery system

FDA grants orphan drug designation for IDN-6556 in liver transplantation

Lorus and Cyclacel enter license agreement for NC-381

PhotoCure's Hexvix nearing approval in Europe

New cannabinoid CB2 ligands prepared and tested at Pharmos

Na+/H+ exchange inhibitors identified by Aventis researchers

Nippon Zoki claims novel tachykinin antagonists, their preparation and use

Novel sodium channel blockers covered by Boehringer Ingelheim patent

Selective MAO-B inhibitors with utility in Alzheimer's disease and senile dementia

New neuropeptide Y5 receptor antagonists described by Roche

Novartis presents new CB1 agonists for pain and other disorders

Toyama and Eisai submit NDA for antirheumatic drug T-614

Maxim completes enrollment for phase III trial of Ceplene with IL-2

Phase III hepatitis C trial of Zadaxin enrolled

Voltage-gated sodium channel blockers with preference for the inactivated state of the channel

Dual-target hybrid antibiotics designed at Microbiotix

OCID-0050, a new investigational oxazolidinone for resistant staphylococcal infections

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...